Among the various applications of human fibrinogen, cardiac surgery stands out as the largest and most critical segment. The complex nature of heart surgeries and the use of cardiopulmonary bypass create a high demand for this essential clotting factor. This segment's dominance is a key factor shaping the overall demand and growth of the Human Fibrinogen Market, which is projected to see steady expansion in the coming years.

The primary reason for this dominance is the unique physiological challenges of cardiac surgery. During procedures like coronary artery bypass grafting (CABG) or valve replacement, patients are placed on a heart-lung machine. This process, known as cardiopulmonary bypass, can lead to significant hemodilution and activation of the coagulation system, often resulting in an acquired fibrinogen deficiency. Without adequate fibrinogen, patients are at high risk of severe post-operative bleeding. Administering fibrinogen concentrate allows surgeons to rapidly correct this deficiency and achieve hemostasis.

Furthermore, the patient population undergoing cardiac surgery often includes older individuals with multiple comorbidities, making them more vulnerable to bleeding complications. The use of human fibrinogen helps reduce the need for allogeneic blood transfusions, which carry risks of infection and adverse reactions. As the number of cardiac procedures continues to rise globally due to an aging population and increasing prevalence of heart disease, the demand for human fibrinogen in this application is expected to remain strong, solidifying its position as the market leader.

People Also Ask

Why is fibrinogen important in heart surgery?
Heart surgery can cause a drop in fibrinogen levels, leading to a risk of excessive bleeding. Fibrinogen concentrate is used to restore levels and ensure proper clotting.

What are the alternatives to human fibrinogen for bleeding?
Alternatives include fresh frozen plasma (FFP) and cryoprecipitate, but fibrinogen concentrate offers advantages like rapid administration and a higher, more predictable dose of fibrinogen.

The critical need for effective bleeding management in cardiac procedures ensures that this segment will continue to be a primary driver of the human fibrinogen market.

Tags: #HumanFibrinogen #CardiacSurgery #CardiopulmonaryBypass #Hemostasis #BleedingManagement